Tabrecta FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved May 6, 2020)
Brand name: Tabrecta
Generic name: capmatinib
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Non-Small Cell Lung Cancer
Tabrecta (capmatinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Development timeline for Tabrecta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.